At RSNA23, Heuron showcases pioneering AI solutions for strokes, unveiling the Heuron StroCare Suite, including the ELVO component. The study demonstrated ELVO’s significant impact on diagnosing emergent large vessel occlusions using non-contrast CT scans. Heuron’s CEO, Dr. Donghoon Shin, emphasizes their commitment to introducing cutting-edge AI technology globally.
Heuron, a pioneering company specializing in medical AI imaging software solutions, led by CEO Dr. Donghoon Shin, is set to participate in the highly anticipated 2023 Radiological Society of North America (RSNA) conference, taking place in Chicago this month. The company has planned a comprehensive display at its exhibition booth and will present groundbreaking research abstracts during the event.
At this prestigious conference, Heuron will unveil its remarkable innovations, including the Heuron AgingCare Suite, a diagnostic support solution harnessing MRI technology for degenerative brain diseases. Additionally, the company will showcase the Heuron StroCare Suite, a comprehensive diagnostic support system for strokes based on non-contrast CT scans. Notably, they will feature the Veuron-Brain-pAb3, which recently received the esteemed certification (510(k) Clearance) from the U.S. FDA. Alongside presenting these advancements, Heuron will provide attendees with live demonstrations, offering valuable insights into how each product optimizes workflow, enhances diagnostic precision, and boosts reading efficiency.
Furthermore, Heuron will present its research abstract, unveiling the clinical evaluation findings of Heuron ELVO, a component within the Heuron StroCare Suite. This component is meticulously designed to automatically identify patients exhibiting suspected emergent large vessel occlusions.
Traditionally, diagnosing and treating strokes begin with a non-contrast CT scan to rule out cerebral hemorrhage. Subsequently, if hemorrhage is absent, clinicians may proceed with a CT angiography to detect large vessel occlusion, shaping subsequent treatment decisions. However, the ability to identify patients requiring immediate intervention solely from the initial non-contrast CT scan, without the necessity for CT angiography, could significantly reduce treatment time, thus enhancing patient outcomes and survival rates.
The study conducted compared the accuracy of identifying patients with emergent large vessel occlusions using non-contrast CT images, both with and without reference to the analysis results provided by Heuron ELVO. The findings indicated that Heuron ELVO markedly enhances clinical efficiency by empowering physicians to make quicker and more precise diagnoses.
Dr. Donghoon Shin, CEO of Heuron, expressed, “Through this momentous gathering of global medical imaging experts and industry professionals, we aim to introduce Heuron’s groundbreaking product portfolio and our unparalleled AI technology to the worldwide market. We are dedicated to actively advocating for the widespread adoption of Heuron’s AI solutions in the medical field across diverse countries.”
Heuron’s participation at RSNA23 underscores their commitment to advancing medical AI technology. The showcased StroCare Suite, especially the ELVO component, promises quicker and more precise stroke diagnoses. Dr. Donghoon Shin’s dedication to global adoption reflects Heuron’s mission to transform stroke care worldwide.
